The Ministry of Health calculates the lists of drugs not produced in Russia
The Ministry of Health calculates lists of old drugs not produced in Russia. The Ministry turned to its main freelance specialists with the proposed replacement of drugs, pharmacologists – in the regions. About it the authors Vedomosti, citing a letter from the Ministry of Health and an appeal by the chief clinical pharmacologist of the Ministry of Health, Vladimir Petrov, to selected colleagues.
According to representatives of the Ministry of Health, work with lists of industrial goods in case of a battle in logistics, when a temporary replacement of drugs may be required. The representative of the Ministry of Health assured that all pharmaceutical manufacturers continue to work on the Russian market, deliveries are on schedule, and the department is not found to be in short supply for any group of drugs. The Russian permissions website published information that is an open search for essential and prescribed drugs (VED): the authorities prescribe the prescription of drugs from their list and their availability in warehouses from manufacturers, wholesalers and pharmacies.
Yevgeny Nifantyev, a member of the State Duma Committee on Industry and Trade, explained that the letter from the Ministry of Health refers to interchangeable intratherapeutic groups. “Clinical pharmacologists make nutritional recommendations about which antibiotic or viral drug can be substituted for another. And pharmacists and pharmacists have a special prescription for drugs for the current disease, that is, only direct generics, ”said the deputy from United Russia. The Ministry of Health will resume work for the future, while foreign pharmaceutical companies continue to supply vital and essential drugs to Russia, said Nikolay Bespalov, development director of the RNC Pharma analytical company.
Advertising on Forbes
Sergey Shulyak, CEO of the analytical company DSM Group, called the early approach of the Ministry of Health soon: when there is a shortage of a filter, it will be too late to prepare. Bespalov added that it would be rational if the collection of information about possible analogues did not involve specialists in a federal institution. Bespalov and Shulyak believe that in the letters of the Ministry of Health and the chief pharmacologist, the deficit is primarily understood as the lack of patented drugs created on the basis of a new pharmaceutical formula, that is, original drugs. The exact share of such drugs in the Russian market was considered difficult.
Bespalov noted that patients with oncological, cardiovascular and rare diseases, as well as people with HIV, are most sensitive to disappearance. Cancer patients are very anxious about the medication, Olga Goldman, director of the Yasnoye Utro mental health service, said. Delays in receiving cancer patients have properties associated with the likelihood of their increase, and a possible shortage of initial drugs that cause a reaction to the effectiveness of therapy, including due to side effects, is difficult to stop, the expert said.
The presence of progressive diseases of the latest generations is extremely important for success in the development of oncology, “14 high-cost nosologies” (hemophilia, cystic fibrosis, etc.) and orphan diseases (Lenegra’s disease, progressive familial heart block, etc.), Shulyak added. In the residual efficiency of previous generations, it still remains high, it remains high. “We have a lot of generics in our country, people continue to be treated,” the source said.
As of indefinite control, products can be collected for delivery from other manufacturers from foreign countries or localization of their emissions in Russia. According to Bespalov, this can become a company for China, India, Brazil, and Southern Europe.
Russia has established the production of medicines if foreign companies stop deliveries, said that it could, in turn, on March 27, the Minister of Industry and Trade Denis Manturov on the air of the Rossiya 1 TV channel. In 2021, in physical terms (5.2 billion packs), 61.2% of in-kind terms (5.2 billion packs) were detected, a representative of the Ministry of Industry and Trade said. According to him, from the list of vital and essential drugs, which includes 808 positions, the domestic pharmaceutical company has the technological ability to produce within the country in a full cycle only in half of the cases.